Cell Painting

Last updated


The Cell Painting assay is a high-content, high-throughput imaging technique used to capture a wide array of cellular phenotypes in response to diverse perturbations.. [1] These phenotypes, often termed "morphological profiles", can be used to understand various biological phenomena, including cellular responses to genetic changes, drug treatments, and other environmental changes. [2] This has been adopted by many pharmaceutical companies in profiling compounds including Recursion Pharmaceutical [3] and AstraZeneca [4]

Contents

Methodology

In the Cell Painting assay, cells are stained with six fluorescent dyes that mark different cellular compartments, including nuclei, cytoplasm, endoplasmic reticulum, Golgi apparatus, mitochondria, and actin. High-resolution images are then captured using automated fluorescence microscopy, and image analysis algorithms are applied to extract thousands of morphological features. [5] These features form the basis of the morphological profile for each perturbation. [6]

Applications

Given its ability to capture a wide array of cellular responses, the Cell Painting assay has become a powerful tool in the field of drug discovery. [7] By comparing the morphological profiles of cells treated with different compounds, researchers can identify potential drug candidates, toxicity [8] or understand the mechanism of action of existing drugs. [9] [10] In combination with genetic perturbations, the assay can be used to determine the function of genes or to understand the underlying mechanisms of genetic diseases. [11] By observing how cells from disease models differ in their morphological profiles from healthy cells, researchers can gain insights into disease mechanisms and potential therapeutic interventions. [12]

Limitations and Challenges

While the Cell Painting assay offers a wealth of information, it's not without its challenges. The high dimensionality of the data requires sophisticated computational tools for analysis. Additionally, the interpretation of morphological profiles in terms of underlying biology can sometimes be non-trivial. [13] With advancements in imaging technology and machine learning, the resolution and depth of morphological profiles are expected to increase, allowing for even more detailed insights into cellular biology. Additionally, as the scientific community continues to generate data using the Cell Painting assay, there's a push towards creating shared repositories to facilitate collaborative research and data-driven discoveries. [14]

Notable Scientists and Contributions

See Also

Notable Works

  1. Bray, Mark-Anthony; Singh, Shantanu; Han, Han; Davis, Chadwick T; Borgeson, Blake; Hartland, Cathy; Kost-Alimova, Maria; Gustafsdottir, Sigrun M; Gibson, Christopher C; Carpenter, Anne E (2016-08-25). "Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes". Nature Protocols . 11 (9): 1757–1774. doi:10.1038/nprot.2016.105. ISSN  1754-2189.

Related Research Articles

In vitro toxicity testing is the scientific analysis of the toxic effects of chemical substances on cultured bacteria or mammalian cells. In vitro testing methods are employed primarily to identify potentially hazardous chemicals and/or to confirm the lack of certain toxic properties in the early stages of the development of potentially useful new substances such as therapeutic drugs, agricultural chemicals and food additives.

<span class="mw-page-title-main">Effector (biology)</span> Small molecule affecting biological activity

In biology, an effector is a general term that can refer to several types of molecules or cells depending on the context:

Plate readers, also known as microplate readers or microplate photometers, are instruments which are used to detect biological, chemical or physical events of samples in microtiter plates. They are widely used in research, drug discovery, bioassay validation, quality control and manufacturing processes in the pharmaceutical and biotechnological industry and academic organizations. Sample reactions can be assayed in 1-1536 well format microtiter plates. The most common microplate format used in academic research laboratories or clinical diagnostic laboratories is 96-well with a typical reaction volume between 100 and 200 µL per well. Higher density microplates are typically used for screening applications, when throughput and assay cost per sample become critical parameters, with a typical assay volume between 5 and 50 µL per well. Common detection modes for microplate assays are absorbance, fluorescence intensity, luminescence, time-resolved fluorescence, and fluorescence polarization.

CellProfiler is free, open-source software designed to enable biologists without training in computer vision or programming to quantitatively measure phenotypes from thousands of images automatically. Advanced algorithms for image analysis are available as individual modules that can be placed in sequential order together to form a pipeline; the pipeline is then used to identify and measure biological objects and features in images, particularly those obtained through fluorescence microscopy.

In medicine, a biomarker is a measurable indicator of the severity or presence of some disease state. It may be defined as a "cellular, biochemical or molecular alteration in cells, tissues or fluids that can be measured and evaluated to indicate normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention." More generally a biomarker is anything that can be used as an indicator of a particular disease state or some other physiological state of an organism. According to the WHO, the indicator may be chemical, physical, or biological in nature - and the measurement may be functional, physiological, biochemical, cellular, or molecular.

<span class="mw-page-title-main">Mechanism of action</span> Biochemical interaction through which a drug produces its pharmacological effect

In pharmacology, the term mechanism of action (MOA) refers to the specific biochemical interaction through which a drug substance produces its pharmacological effect. A mechanism of action usually includes mention of the specific molecular targets to which the drug binds, such as an enzyme or receptor. Receptor sites have specific affinities for drugs based on the chemical structure of the drug, as well as the specific action that occurs there.

High-content screening (HCS), also known as high-content analysis (HCA) or cellomics, is a method that is used in biological research and drug discovery to identify substances such as small molecules, peptides, or RNAi that alter the phenotype of a cell in a desired manner. Hence high content screening is a type of phenotypic screen conducted in cells involving the analysis of whole cells or components of cells with simultaneous readout of several parameters. HCS is related to high-throughput screening (HTS), in which thousands of compounds are tested in parallel for their activity in one or more biological assays, but involves assays of more complex cellular phenotypes as outputs. Phenotypic changes may include increases or decreases in the production of cellular products such as proteins and/or changes in the morphology of the cell. Hence HCA typically involves automated microscopy and image analysis. Unlike high-content analysis, high-content screening implies a level of throughput which is why the term "screening" differentiates HCS from HCA, which may be high in content but low in throughput.

<span class="mw-page-title-main">Protein aggregation</span> Accumulation of clumps of misfolded or disordered proteins

In molecular biology, protein aggregation is a phenomenon in which intrinsically-disordered or mis-folded proteins aggregate either intra- or extracellularly. Protein aggregates have been implicated in a wide variety of diseases known as amyloidoses, including ALS, Alzheimer's, Parkinson's and prion disease.

<span class="mw-page-title-main">BacMam</span>

Baculovirus gene transfer into Mammalian cells, known from scientific research articles as BacMam, is the use of baculovirus to deliver genes to mammalian cells. Baculoviruses are insect viruses that can be modified to express proteins in mammalian cells. The unmodified baculovirus is able to enter those cells; however, its genes are not expressed unless a mammalian recognizable promoter is incorporated upstream of a gene of interest. Both unmodified baculovirus and its modified counterpart are unable to replicate in humans and are thus non-infectious.

Phenotypic screening is a type of screening used in biological research and drug discovery to identify substances such as small molecules, peptides, or RNAi that alter the phenotype of a cell or an organism in a desired manner. Phenotypic screening must be followed up with identification and validation, often through the use of chemoproteomics, to identify the mechanisms through which a phenotypic hit works.

<span class="mw-page-title-main">Helen Blau</span> American biochemist

Helen Margaret Blau is an American biologist and the Donald E. and Delia B. Baxter Foundation Professor and Director of the Baxter Laboratory for Stem Cell Biology at Stanford University School of Medicine. She is known for establishing the reversibility of the mammalian differentiated state. Her landmark papers showed that nuclear reprogramming and the activation of novel programs of gene expression were possible, overturning the prevailing view that the differentiated state was fixed and irreversible. Her discoveries opened the door for cellular reprogramming and its application to stem cell biology.

Chemoproteomics entails a broad array of techniques used to identify and interrogate protein-small molecule interactions. Chemoproteomics complements phenotypic drug discovery, a paradigm that aims to discover lead compounds on the basis of alleviating a disease phenotype, as opposed to target-based drug discovery, in which lead compounds are designed to interact with predetermined disease-driving biological targets. As phenotypic drug discovery assays do not provide confirmation of a compound's mechanism of action, chemoproteomics provides valuable follow-up strategies to narrow down potential targets and eventually validate a molecule's mechanism of action. Chemoproteomics also attempts to address the inherent challenge of drug promiscuity in small molecule drug discovery by analyzing protein-small molecule interactions on a proteome-wide scale. A major goal of chemoproteomics is to characterize the interactome of drug candidates to gain insight into mechanisms of off-target toxicity and polypharmacology.

Shantanu Chowdhury is an Indian structural biologist and a professor at Institute of Genomics and Integrative Biology of the Council of Scientific and Industrial Research. He is known for developing a mechanism for gene regulation mediated by DNA Secondary-Structure in diverse cellular contexts. An elected fellow of the National Academy of Sciences, India, he is a recipient of the National Bioscience Award for Career Development of the Department of Biotechnology in 2010. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, one of the highest Indian science awards, in 2012, for his contributions to biological sciences.

<span class="mw-page-title-main">Joseph Kost</span> Chemical engineering researcher

Joseph Kost is an Israeli academic, currently holder of The Abraham and Bessie Zacks Chair in Biomedical Engineering and the past Dean of the Faculty of Engineering Sciences at the Ben-Gurion University of the Negev.

<span class="mw-page-title-main">Anne E. Carpenter</span> American scientist

Anne E. Carpenter is an American scientist in the field of image analysis for cell biology and artificial intelligence for drug discovery. She is the co-creator of CellProfiler, open-source software for high-throughput biological image analysis, and a co-inventor of the Cell Painting assay, a method for image-based profiling. She is an Institute Scientist and Senior Director of the Imaging Platform at the Broad Institute.

D. Lansing Taylor is the Director at the University of Pittsburgh Drug Discovery Institute (UPDDI), Pennsylvania and a faculty member in the Department of Computational and Systems Biology.

Karen L. Leach is an American biochemist with extensive drug discovery experience in large pharmaceutical research laboratories. Her expertise in molecular pharmacology, signal transduction and protein kinases, has been used to establish mechanisms of toxicity for therapeutics such as the novel antibiotic linezolid (Zyvox).

Endothelial cell tropism or endotheliotropism is a type of tissue tropism or host tropism that characterizes an pathogen's ability to recognize and infect an endothelial cell. Pathogens, such as viruses, can target a specific tissue type or multiple tissue types. Like other cells, the endothelial cell possesses several features that supports a productive viral infection a cell including, cell surface receptors, immune responses, and other virulence factors. Endothelial cells are found in various tissue types such as in the capillaries, veins, and arteries in the human body. As endothelial cells line these blood vessels and critical networks that extend access to various human organ systems, the virus entry into these cells can be detrimental to virus spread across the host system and affect clinical course of disease. Understanding the mechanisms of how viruses attach, enter, and control endothelial functions and host responses inform infectious disease understanding and medical countermeasures.

<span class="mw-page-title-main">Peter Karl Sorger</span> American cancer biologist (born 1961)

Peter Karl Sorger is a systems and cancer biologist and Otto Krayer Professor of Systems Pharmacology in the Department of Systems Biology at Harvard Medical School. Sorger is the founding head of the Harvard Program in Therapeutic Science (HiTS), director of its Laboratory of Systems Pharmacology (LSP), and co-director of the Harvard MIT Center for Regulatory Science. He was previously a Professor of Biology and Biological Engineering at the Massachusetts Institute of Technology where he co-founded its program on Computational and Systems Biology (CSBi). Sorger is known for his work in the field of systems biology and for having helped launch the field of computational and systems pharmacology. His research focuses on the molecular origins of cancer and approaches to accelerate the development of new medicines. Sorger teaches Principles and Practice of Drug Development at Massachusetts Institute of Technology and Harvard University.

<span class="mw-page-title-main">Markus Ralser</span> Italian biologist

Markus Ralser is an Italian biologist. His main research interest is metabolism of microorganisms. He is also known for his work on the origin of metabolism during the origin of life, and proteomics.

References

  1. ↑ Bray, Mark-Anthony; Singh, Shantanu; Han, Han; Davis, Chadwick T; Borgeson, Blake; Hartland, Cathy; Kost-Alimova, Maria; Gustafsdottir, Sigrun M; Gibson, Christopher C; Carpenter, Anne E (2016-08-25). "Cell Painting, a high-content image-based assay for morphological profiling using multiplexed fluorescent dyes". Nature Protocols. 11 (9): 1757–1774. doi:10.1038/nprot.2016.105. ISSN   1754-2189. PMC   5223290 . PMID   27560178.
  2. ↑ Kohler, Makenzie; MIT, Broad Institute of; Harvard. "New image-based cellular profiling tool peers deeply into metabolic biology". phys.org. Retrieved 2023-08-13.
  3. ↑ "The subtle art of really big data: Recursion Pharma maps the body". ZDNET. Retrieved 2023-08-13.
  4. ↑ Trapotsi, Maria-Anna; Mouchet, Elizabeth; Williams, Guy; Monteverde, Tiziana; Juhani, Karolina; Turkki, Riku; Miljković, Filip; Martinsson, Anton; Mervin, Lewis (2022-01-18). "Cell morphological profiling enables high-throughput screening for PROteolysis TArgeting Chimera (PROTAC) phenotypic signature". doi:10.1101/2022.01.17.476610 . Retrieved 2023-08-13.
  5. ↑ Bray, Mark-Anthony; Singh, Shantanu; Han, Han; Davis, Chadwick T.; Borgeson, Blake; Hartland, Cathy; Kost-Alimova, Maria; Gustafsdottir, Sigrun M.; Gibson, Christopher C. (2016-04-25). "Cell Painting, an image-based assay for morphological profiling". doi:10.1101/049817 . Retrieved 2023-08-13.
  6. ↑ Bray, Mark-Anthony; Gustafsdottir, Sigrun M; Rohban, Mohammad H; Singh, Shantanu; Ljosa, Vebjorn; Sokolnicki, Katherine L; Bittker, Joshua A; Bodycombe, Nicole E; Dančík, Vlado; Hasaka, Thomas P; Hon, Cindy S; Kemp, Melissa M; Li, Kejie; Walpita, Deepika; Wawer, Mathias J (2017-01-07). "A dataset of images and morphological profiles of 30 000 small-molecule treatments using the Cell Painting assay". GigaScience. 6 (12). doi: 10.1093/gigascience/giw014 . ISSN   2047-217X. PMC   5721342 .
  7. ↑ "A technique called Cell Painting could speed drug discovery". MIT Technology Review. Retrieved 2023-08-13.
  8. ↑ Tian, Guangyan; Harrison, Philip J; Sreenivasan, Akshai P; Puigvert, Jordi Carreras; Spjuth, Ola (2022-10-07). "Combining molecular and cell painting image data for mechanism of action prediction". doi:10.1101/2022.10.04.510834 . Retrieved 2023-08-13.
  9. ↑ Pennisi, E. (2016-05-19). "'Cell painting highlights responses to drugs and toxins". Science. 352 (6288): 877–878. doi:10.1126/science.352.6288.877. ISSN   0036-8075.
  10. ↑ Tian, Guangyan; Harrison, Philip J; Sreenivasan, Akshai P; Puigvert, Jordi Carreras; Spjuth, Ola (2022-10-07). "Combining molecular and cell painting image data for mechanism of action prediction". doi:10.1101/2022.10.04.510834 . Retrieved 2023-08-13.
  11. ↑ Settleman, Jeffrey, ed. (2017-01-23). "Decision letter: Systematic morphological profiling of human gene and allele function via Cell Painting". doi: 10.7554/elife.24060.021 .{{cite journal}}: Cite journal requires |journal= (help)
  12. ↑ Caicedo, Juan C.; Arevalo, John; Piccioni, Federica; Bray, Mark-Anthony; Hartland, Cathy L.; Wu, Xiaoyun; Brooks, Angela N.; Berger, Alice H.; Boehm, Jesse S. (2021-11-20). "Cell Painting predicts impact of lung cancer variants". doi:10.1101/2021.11.18.469171 . Retrieved 2023-08-13.
  13. ↑ Chandrasekaran, Srinivas Niranj; Ceulemans, Hugo; Boyd, Justin D.; Carpenter, Anne E. (2020-12-22). "Image-based profiling for drug discovery: due for a machine-learning upgrade?". Nature Reviews Drug Discovery. 20 (2): 145–159. doi: 10.1038/s41573-020-00117-w . ISSN   1474-1776. PMC   7754181 .
  14. ↑ Rahman, Lu (2021-04-15). "Cell painting: a vibrant future for phenotypic drug discovery". Drug Discovery World (DDW). Retrieved 2023-08-13.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.